Applera Accelerates Old Options Vesting

Applera’s board of directors has approved acceleration of the vesting of stock options held by employees and directors, the company said in an SEC filing last week. Options with vesting based on performance and those held by employees in certain foreign companies were not accelerated, the company said. The shares received on exercise held by directors and senior management may not be sold any earlier than the original vesting date, or upon termination.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.